Hi, good afternoon. Congrats on a good set of numbers. First, question on the Middle East war and the raw material price inflation. Do these things have any impact on our operations in terms of availability or cost of reagents, etcetera?
Got it . Now just a couple of bookkeeping questions. One, this entity we have acquired, does that have just one lab or is it a few more labs?
A couple of questions from my side. On one side, we have seen a sharp depreciation in Rupees. and at the same time, we have seen this European Union trade deal which cuts tariffs. Does either of this favourably or unfavourably affect our cost base and can it impact margins?
Okay. And in case these reagent prices actually go up, do you think you can pass them on without impacting volume growth?
Hi, good afternoon, all of you. Congratulations on a great set of quarters. A couple of questions from my side. We have seen the new rates being published by CGHS , and possibly other government agencies will follow. Is there any way in which the stand-alone diagnostic industry benefits from that, and our company in particular?
May I know what percentage of your top line would be benefiting from this, assuming other government agencies also follow.
Hi, good afternoon. Congrats on a great quarter. Just following up on the previous question, the price increase and realization increase that you are talking about, did that kick in Q3? Or was it already there in Q2 and Q1?
Mostly Q3. So, if I look at the kind of growth you delivered in Q1 and Q2 versus Q3, there is a big step jump. And from your competitors, we have not heard about a great season or anything in the healthcare side. So can I assume a significant part of that is coming from this realization improvement?
You partly answered my questions. But I just wanted to know, are you -- have you already tied up some semaglutide contracts for FY '27 within your capacity? Or is it all Liraglutide as of now?
So including semaglutide, you're saying only about 30 million of your 40 million capacity in the like in FY27.
Just a couple of questions. Maybe a little bit follow-up to earlier questions. I was looking at this overall regulated market business, this is stuck at around $95 million plus/minus rang e for last 8 to 10 quarters. Of course, you mentioned that in second half, you have some large products, so you will see some growth. But apart from that, do you have confidence that this business can grow at double digits continuously over the next 5 years? Do we have that visibility?
No, I'm looking at the whole regulated market business as a whole. If some when U.S. grows something else is coming off and something else grows, the U.S. comes off, and the 17% you are talking also has a huge tailwind of currency depreciation. In U.S dollar terms, the growth is not that big. So as a whole, the regulated market business piece , do we have visibility of double- digit growth over the next few years?
Good evening. Could you please elaborate a bit on the Semaglutide manufacturing opportunity for you in the near-term specifically for next financial year. How big can that be based on your capacity, your contracts and your outlook compared to the overall size of the company?
So did I hear it correctly that the entire 140, that is the new 100 as well, will be ready by the end of this financial year by March?
A couple of questions from my side. One, there is this INR25 crores of loss from the peptide franchise, which you have given in the investor presentation. How has this moved across quarters from 1Q to 3Q? And what is the outlook for the next few quarters?
Understood. Just to follow up on that. When you say improvement in performance, are you referring to breakeven and a positive EBITDA sometime soon?
Thanks for the cash flow reconciliation that Anurag offered at the consolidated level. Just wanted to understand at the subsidiary level, at the IGI level. So this entire $700 million, I assume came to IGI. And how much of it is still with IGI?
So out of the $700 million, only $210 million, $220 million goes to IGI. The remaining came to some other entities of Glenmark. Is that right? Is my understanding right?
Can we get a little more clarity on the accounting of the upfront payment we get from AbbVie. From what you said, I understand we will start amortizing it in Q3. So what would be the exact amount that would come on P&L?
So how much would that be that amount which will come to the P&L?
Congratulations on a great set of numbers. Just a couple of housekeeping questions from my side. One, what is the total capex for the current year that you are estimating?
The receivable days and inventory days seem to have come down for the midyear balance sheet compared to the March balance sheet and even compared to the earlier balance sheet. Has anything changed there materially?
Congratulations on a great set of numbers. Just a couple of housekeeping questions from my side. One, what is the total capex for the current year that you are estimating?
The receivable days and inventory days seem to have come down for the midyear balance sheet compared to the March balance sheet and even compared to the earlier balance sheet. Has anything changed there materially?
Hi. Good evening. Congratulations on a great set of numbers. A couple of quick clarifications. One, I see that the depreciation and amortization cost has come down this quarter compared to last few quarters. Why is that?
Okay. So, for existing assets, this will be the new level at which there will be D &A. And then as you add assets, it will pick up. Okay. And second, any update on the indoor O&M that you are planning?
A couple of questions. One, Srikakulam 120 beds, have we commissioned it because I haven't seen any addition in the cluster.
What are the plans of expansion beyond FY '27 because right now, all the announced projects are ending Q4 FY '2027…?
Again, congrats on a great set of numbers. Most questions have been answered. Just on your capacity mix. So your presentation talked about more than 5,700 operational beds, bu t what would be the total capacity beds?
Yes.
Most of my questions got answered, just one strategic question on the kind of expansion we are doing. If I look at most of your competitors, they are targeting Tier 1, Tier 2 cities with large 400-500 bed facilities. Whereas if I look at your acquisitions, be it Manesar, Jalandhar, et cetera, you are more going Tier 3, 4 and slightly smaller facilities. Is that the way forward for us?
Understood. Just a related question or digging a little deeper. Mumbai, Bangalore, Kolkata are cities where we are already present. And in these cities, your competitors both listed as well as private probably in the last 2 years h ave -- 2.5 years have announced at least 4, 5 big projects reach, most of them greenfield, which means there is potential and there is land or whatever infra available to develop. But you haven't been so aggressive in those particular geographies in that sense. I mean, is there any reason? Or would you become more aggressive now?
Hi. Good evening. You mentioned your thoughts around the Semaglutide market in Brazil. Do you also mind sharing your thoughts around the market in India as it opens up and your plans?
Okay, got it. Thank you.
Just following up from a couple of previous questions. Umang, Revlimid, has it changed Q -o-Q over the last 3 quarters, say, Q3, Q4, Q1? Or is it broadly similar?
Yes, correct.
Umang, are we still expecting to launch Symbicort in FY '27?
Okay. And sir, there is this product Teduglutide in which you and your partner have filed a -- filed for a declaratory judgment. Could you give some details about when do you expect to launch this?
A couple of questions from my side. When do you expect your tax rate to normalize at the consolidated level?
But in the entities where you are making losses, you would be also taking some tax credit on the P&L, right?